Patients with atrial fibrillation and heart failure experience an increased morbidity and mortality from the hemodynamic consequences of atrial fibrillation and an increased stroke risk. Consequently, there has been increased attention to procedural alternatives to pharmacologic rhythm control and anticoagulation for stroke prevention. This review aims to evaluate the evidence for atrial fibrillation ablation and left atrial appendage closure in heart failure patients.
INTRODUCTION
The estimated prevalence of heart failure in the United States is 5.7 million, and, unlike other major cardiovascular diseases, the prevalence, incidence and mortality from heart failure are increasing [1] [2] [3] . Of particular concern are patients with both heart failure and atrial fibrillation. There is a distinct correlation between these two conditions, with the prevalence of atrial fibrillation rising from 10% in mild cases of heart failure to almost 50% in severe heart failure [4] . This correlation has been attributed to an increase in morbidity and mortality among patients with atrial fibrillation and heart failure [5, 6] . Although restoration of sinus rhythm could lead to improved left ventricular systolic and diastolic function [7] [8] [9] , rhythm control with cardioversion and antiarrhythmic drugs has not been shown to reduce mortality [10] . Consequently, there has been increased use of catheter ablation to restore sinus rhythm in an attempt to improve the effects of atrial fibrillation in heart failure patients [11] .
In addition to the hemodynamic consequences of atrial fibrillation in these patients, the concern for cardioembolic stroke remains. Patients with atrial fibrillation and heart failure have a three-fold increased risk of stroke [12] . Although anticoagulation has been shown to be effective [13] , only 60% of
EARLY STUDIES OF ATRIAL FIBRILLATION ABLATION IN HEART FAILURE PATIENTS
Given the challenges of pharmacotherapy for maintaining sinus rhythm in patients with atrial fibrillation [10, 17] , attention has shifted to ablation therapy for rhythm control. Initial studies evaluating the safety and efficacy of atrial fibrillation ablation in heart failure patients consisted of small, nonrandomized studies [18] [19] [20] [21] [22] [23] [24] [25] . With current catheter ablation techniques, the risk of major complications from atrial fibrillation ablation in heart failure patients has been estimated in a recent metaanalysis to be 4.2% [95% confidence interval (CI) 3.6-4.8] [26 && ]. This complication rate is similar to that observed in atrial fibrillation ablation performed in patients without heart failure [27] .
Early studies demonstrate a wide variation in the efficacy of atrial fibrillation ablation in heart failure patients. The success rate in restoring sinus rhythm following the first procedure ranged from 25 to 73% [26 && ,28] . This range was influenced by the baseline characteristics of the study population, type of atrial fibrillation and ablation protocol. Not surprisingly, aggregated initial efficacy data of atrial fibrillation ablation in heart failure patients estimate a success rate of 40% in restoring sinus rhythm [26 && ]. Although this rate is lower than initial efficacy rates of atrial fibrillation ablation in patients without heart failure, after multiple procedures, the overall success rate of atrial fibrillation ablation in patients with heart failure was found to be 60% in a recent meta-analysis [26 && ]. To obtain this overall success rate of atrial fibrillation ablation, more repeat procedures were required in patients with heart failure to maintain sinus rhythm [19, 29] . Emerging technology, namely the use of irrigated, contact force sensing ablation catheters, may increase the efficacy of atrial fibrillation ablation in patients with heart failure. Results from several studies in the general population have already shown an increased freedom from atrial fibrillation recurrence when appropriate contact force was maintained during atrial fibrillation ablation [30, 31] .
Despite the wide variation in efficacy seen in the early nonrandomized trials of atrial fibrillation ablation in heart failure patients, the clinical impact of restoring sinus rhythm in these patients has been consistently favorable. These studies demonstrate either a significant improvement in left ventricular ejection fraction (LVEF), echocardiographic indices, or quality-of-life scores following ablation [18] [19] [20] [21] [22] [23] 25] . These studies provide convincing evidence demonstrating the safety and efficacy of atrial fibrillation ablation in this population.
RANDOMIZED TRIALS OF ATRIAL FIBRILLATION ABLATION IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION
To date there have been four randomized controlled trials investigating atrial fibrillation ablation in patients with heart failure and left ventricular systolic dysfunction (Table 1 ). The first randomized trial compared atrial fibrillation ablation with atrioventricular node ablation followed by biventricular pacing [32] . Patients with drug-resistant atrial fibrillation and LVEF less than 40% with New York Heart Association class II or III symptoms were randomized to treatment and followed up for 6 months. The study found that patients who underwent atrial fibrillation ablation had better quality-of-life measurements, better performance on 6-min walk test, and a higher improvement in LVEF.
These findings were not reproduced in the second randomized controlled trial, by MacDonald et al. [33] , which randomized persistent atrial fibrillation patients with New York Heart Association class II-IV symptoms and LVEF less than 35% to atrial fibrillation ablation or optimal rate control medications. At 6-month follow-up, there was no significant difference between the two groups in LVEF or two of the three quality-of-life measurements. Limitations of the study included the fact that sinus rhythm was only achieved in 50% of the patients randomized to atrial fibrillation ablation.
KEY POINTS
Safety and overall efficacy of atrial fibrillation ablation in heart failure patients are comparable to those of atrial fibrillation ablation performed in patients without heart failure, although more repeat procedures are required in the heart failure population.
Short-term and long-term evidence of significant clinical benefit of atrial fibrillation ablation in patients with LV systolic dysfunction.
Limited evidence for the role of atrial fibrillation ablation in patients with HFpEF.
Insufficient data regarding the safety and efficacy of LAA closure in heart failure patients.
Subgroup analysis demonstrated that those who maintained sinus rhythm did have an improved LVEF.
In contrast, two recent randomized controlled trials suggest a clinical benefit to rhythm control with catheter ablation in heart failure patients and depressed LVEF. The ARC-HF study (A Randomized Trial to Assess Catheter Ablation Versus Rate Control in the Management of Persistent Atrial Fibrillation in Heart Failure) analyzed catheter ablation for patients with persistent atrial fibrillation, symptomatic heart failure, and LVEF 35% or less [34 & ]. Fiftytwo patients were randomized in an intention-totreat analysis, for extensive catheter ablation including pulmonary vein isolation, linear ablation lesions along the left atrial roof, and mitral isthmus, targeting of complex fractionated atrial electrograms, and linear ablation along the cavotricuspid isthmus. In the patients who underwent ablation, single-procedure success was 72% and overall success after multiple procedures was 92% off antiarrhythmic drugs. The study demonstrated a significant increase in the primary endpoint of peak oxygen consumption at 12 months in the catheter ablation arm versus the rate control arm by a mean difference of 3.07 ml/kg/min (95% CI 0.56-5.59). This difference in peak oxygen consumption between the two groups was not observed at 3 months, suggesting a progressive improvement in peak oxygen consumption following atrial fibrillation ablation. Similar trends favoring ablation occurred in improvements in quality of life as measured by the Minnesota Living with Heart Failure Questionnaire and reduction in B-type natriuretic peptide (BNP). LVEF also significantly increased in the ablation group from 21.5 AE 8.3% at baseline to 32.8 AE 14.3% at 12 months (P < 0.001). However, when compared with the rate-control arm, these changes showed only a nonsignificant trend toward improvement. The ARC-HF findings are not trivial. Prior studies have suggested a 7% reduction in all-cause mortality in patients with heart failure with every 6% increase in peak oxygen consumption [36, 37] . This study demonstrated at mean improvement in peak oxygen consumption of 19.9% (95% CI 3.9-35.9) in the ablation group compared with the rate control group.
The most recent CAMTAF trial (A Randomized Controlled Trial of Catheter Ablation Versus ]. The primary endpoint of the study analyzed differences in LVEF between the two groups at 6 months.
Fifty patients comprised the study population, with 26 patients undergoing catheter ablation. Patients underwent an ablation protocol similar to that of the ARC-HF study. The single-procedure success rate off antiarrhythmic drugs was 38% at 1 year. Most patients required more than one procedure, with an overall success rate of 81% following all procedures at 6 months and 73% at 1 year. At 6 months, the study demonstrated a significant difference in LVEF between the two groups. The LVEF in the catheter ablation group was 39.9% (95% CI 35.2-44.7) versus 31.9% (95% CI 25.5-36.6) in the medical group (P ¼ 0.015). The difference in LVEF between the two groups was evident after 1 month and was sustained at 1 year. Similar statistically significant differences were observed in changes in left ventricular end systolic volume, peak oxygen consumption, plasma BNP, and quality of life as measured with the Minnesota Living with Heart Failure Questionnaire. The study results suggest a marked benefit in atrial fibrillation ablation in heart failure patients when compared with medical rate control alone. In fact, five of the 26 patients who underwent atrial fibrillation ablation, had complete normalization of LVEF and resolution of heart failure symptoms at 6 months.
The findings in ARC-HF and CAMTAF trial build on the foundation of the earlier atrial fibrillation and heart failure ablation studies. The study by MacDonald et al. [33] has been the only randomized controlled trial that failed to show benefit for atrial fibrillation ablation in heart failure patients. This study achieved an overall procedural success rate of only 50% with just 6 months of follow-up, factors which would have strongly contributed to the observed lack of benefit of atrial fibrillation ablation in heart failure patients.
LONG-TERM EFFICACY OF ATRIAL FIBRILLATION ABLATION IN THE SETTING OF IMPAIRED LEFT VENTRICULAR SYSTOLIC FUNCTION
There are only a handful of recent studies that have looked at the long-term efficacy of atrial fibrillation ablation in patients with left ventricular systolic dysfunction [38 && ,39 & ]. In a prospective casecontrol study, patients with LVEF 40% or less underwent atrial fibrillation ablation, after which antiarrhythmic drugs were discontinued and serial Holter electrocardiographic and echocardiographic monitoring was performed. The study demonstrated a statistically significant reduction in heart failure symptoms and an increase in LVEF from 33 AE 6% at baseline to 48 AE 13% at 24 months (P < 0.001). In fact, 44% of the study population experienced marked improvements in LVEF of at least 20% with multivariate regression analysis demonstrating baseline heart rate and rhythm outcome as the only independent predictors of improvement in LVEF.
In subgroup analysis, patients who maintained sinus rhythm following atrial fibrillation ablation had significantly greater improvements in LVEF from baseline compared with those with recurrence of atrial tachycardia/fibrillation. This observation was not observed at 6 months, but only after 12 and 24 months of follow-up, suggesting that the initial LVEF improvement at 6 months was due to changes from baseline heart rate rather than rhythm outcome, whereas LVEF improvements at 12 and 24 months were due to changes resulting from both baseline heart rate and rhythm outcome. Furthermore, supporting this observation is the analysis performed by the study authors that found that only rhythm outcome following atrial fibrillation ablation was associated with improvements in LVEF at 12 and 24 months after controlling for heart rate at 6 months.
Thus, both baseline heart rate and rhythm outcome following ablation appear to be predictors of LVEF improvement in heart failure patients undergoing atrial fibrillation ablation. Interestingly, the relative importance of baseline heart rate and rhythm outcome may vary over time, with the initial improvement in LVEF associated with rate control and later improvements in LVEF associated with sustained rhythm control. This finding supports the hypothesis that restoration of regular atrial contractility and resynchronization of atrioventricular contractions are both important to left ventricular remodeling in atrial fibrillation patients with heart failure.
These findings have been strengthened by a recently published systematic review and metaanalysis by Anselmino et al. Atrial fibrillation recurrence was consistently defined as atrial fibrillation/tachycardia occurring for at least 30 s following an initial blanking period of 3 months after procedure. Initial procedural efficacy in restoring sinus rhythm ranged from 36 to 44%, whereas overall procedural efficacy was 60%, consistent with results of atrial fibrillation ablation in the general population [40] .
All of the studies in this review demonstrated an improvement in LVEF over the follow-up period, with mean LVEF improving from 40 to 53%, with a commensurate decrease in mean N-terminal pro-BNP levels from 1187 pg/ml prior to ablation to 567 pg/ml by the end of the follow-up period (P < 0.001). This study remains the largest systematic review and meta-analysis of atrial fibrillation ablation in patients with left ventricular systolic dysfunction to date. Although these studies show long-term improvements in LVEF and clinical heart failure symptoms following atrial fibrillation ablation, further benefit with regard to heart failure hospitalization and mortality has not been assessed.
ATRIAL FIBRILLATION ABLATION IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION
The association between atrial fibrillation and heart failure is not unique to patients with left ventricular systolic dysfunction. The estimated prevalence of atrial fibrillation among patients with heart failure with preserved ejection fraction (HFpEF) ranges from 20 to 40% [41, 42] . The irregular and rapid ventricular rate with short ventricular filling time has been shown to reduce cardiac output and is implicated in the progression of HFpEF [43] . To date, there has only been one study investigating the efficacy of catheter ablation in patients with atrial fibrillation and preserved ejection fraction [44 && ]. The prospective, single-center study looked at 74 consecutive patients with HFpEF who underwent atrial fibrillation ablation. Antiarrhythmic drugs were discontinued prior to ablation, during which patients underwent pulmonary vein isolation, linear ablation along the left atrial roof, isolation of the superior vena cava, targeting of complex fractionated atrial electrograms and linear ablation along the cavotricuspid isthmus. If sinus rhythm was not restored with this protocol, direct current cardioversion was performed.
Patients were followed at regular intervals with 24-h Holter monitoring to detect atrial fibrillation recurrence. Atrial fibrillation recurrence was defined as any atrial tachyarrhythmia more than 30 s after a 3-month postprocedure blanking period. During a mean follow-up period of 34 AE 16 months, the single-procedure success rate was 27% and the multiple-procedure success rate was 45% off antiarrhythmic drugs. The multiple-procedure success rate with antiarrhythmic drugs was 73%. Subgroup analysis showed that more patients with longstanding persistent atrial fibrillation failed to maintain sinus rhythm after ablation. In multivariate analysis, type of atrial fibrillation [hazard ratio ¼ 1.81 (95% CI 1.03-3.17, P ¼ 0.03)] and lack of hypertension [hazard ratio ¼ 0.49 (95% CI 0.24-0.96, P ¼ 0.04)] were the only two independent predictors of maintaining sinus rhythm following atrial fibrillation ablation.
The study also looked at changes in echocardiographic parameters associated with HFpEF. In patients in whom sinus rhythm was maintained, LVEF significantly increased and E/E 0 ratio significantly decreased. There was no change from baseline in LVEF or E/E 0 ratio in the group with atrial fibrillation recurrence after ablation. Changes from baseline in left ventricular strain and strain rate were also noted in the patients in whom sinus rhythm was maintained.
The success rate of atrial fibrillation ablation off antiarrhythmic drugs in this study of HFpEF patients was quite low [45, 46] , which may be due to the role of left ventricular diastolic dysfunction in LA remodeling [47] . This is supported by the findings that atrial fibrillation type and absence of hypertension, both of which relate to diastolic dysfunction, were independent predictors of procedural success [48] . Thus, long-term maintenance of sinus rhythm in this population may serve to improve HFpEF by improving left ventricular strain, improved left ventricular diastolic function and LA function.
LEFT ATRIAL APPENDAGE CLOSURE IN HEART FAILURE PATIENTS
Several LAA closure or exclusion devices have been developed as an alternative to anticoagulation in patients with atrial fibrillation. They include the WATCHMAN (Boston Scientific, Natick, Massachusetts, USA), LARIAT (SentreHeart, Redwood City, California, USA), Amplatzer Cardiac Plug (St Jude Medical, Minneapolis, Minnesota, USA), WaveCrest LAA occluder (Coherex Medical, Salt Lake City, Utah, USA) and the LAmbre LAA occluder (Lifetech Scientific Corp, Shenzhen, China) [49] . The data regarding the safety and efficacy of these devices are limited. Most of the published literature has focused on the LARIAT and WATCHMAN devices (Fig. 1) .
The LARIAT device, a percutaneous epicardial suture delivery device with US Food and Drug Administration approval, has been used in almost 2000 patients in the United States [50] . There have been no randomized controlled trials investigating the LARIAT device to date. Recent studies evaluating the safety and efficacy of the LARIAT device have reported acute procedural success rates ranging from 93 to 100% [51, 52, 53 & ,54
Although studies have claimed low adverse event rates, the true safety profile of the LARIAT device is yet to be fully characterized [51, 52] . In the largest multicenter retrospective study of 154 patients, in which 34% of the study population had a history of heart failure, the major complication rate was 9. ]. In this longer-term follow-up, the WATCHMAN device met the criteria for both noninferiority and superiority when compared with warfarin for preventing the combined outcome of stroke, systemic embolism and cardiovascular/unexplained death. The observed event rate in the WATCHMAN group was 8.4% versus an event rate of 13.9% in the warfarin group [hazard ratio ¼ 0.61 (95% CI 0.38-0.97, P ¼ 0.04)].
The longer-term follow-up study found that the WATCHMAN group had fewer hemorrhagic strokes and fewer cardiovascular deaths when compared with the warfarin group. Rates of all stroke and ischemic stroke did not differ between the two groups. More importantly, the study also met the criteria for WATCHMAN superiority with regard to cardiovascular mortality [hazard ratio ¼ 0.40 (95% CI 0.21-0.75, P ¼ 0.005)] and all-cause mortality [hazard ratio ¼ 0.66 (95% CI 0.45-0.98, P ¼ 0.040)]. In a subgroup analysis differentiated by a median LVEF of 60%, the primary efficacy endpoint was consistent for LVEF at least 60% or less than 60%.
Concerns remain regarding the paucity of current data that exist for LAA closure/exclusion devices in the heart failure population, especially those with significant left ventricular dysfunction. There is evidence that patients with left ventricular dysfunction are predisposed to left atrial as well as LAA thrombi [50] . This calls into question any strategy that promotes LAA closure without longterm anticoagulation in those patients with atrial fibrillation and heart failure.
CONCLUSION
Atrial fibrillation ablation in heart failure patients with left ventricular systolic dysfunction has been shown to have a complication rate comparable to atrial fibrillation ablation performed in the general population. The overall efficacy is comparable to that seen in patients without heart failure; however, studies note increased atrial fibrillation recurrences requiring more repeat procedures. When patients are successfully restored to sinus rhythm, the clinical benefits include improvements in LVEF, The LARIAT device enables ligation of the LAA through the deployment of a pretied suture loop using a combined transseptal approach and subxiphoid pericardial access [49] .
(b) WATCHMAN device consisting of a self-expanding nitinol frame with a polyethylene terephthalate fabric cap that is positioned and secured within the LAA [49] . LAA, left atrial appendage.
peak oxygen consumption, quality of life and overall clinical heart failure symptoms. More randomized studies with long-term follow-up are needed to determine whether morbidity and mortality are affected by atrial fibrillation ablation in patients with atrial fibrillation and heart failure. Two pending trials, both due for completion in 2016, RAAFT AF (A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation) and CASTLE-AF (Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation), will help answer these questions. There are currently insufficient data to determine the safety and efficacy of LAA closure/exclusion procedures in the heart failure population. Further trials are required to investigate the safety as well as overall benefit when compared with warfarin and novel oral anticoagulants. 
